Quadrivalent HPV vaccine,
does it really help with Prevention of vaccine-type HPV-related external genital lesions and genital warts in males aged 16 to 26 years?
research showsThe quadrivalent HPV vaccine is rated B because a randomized trial showed prevention of HPV 6/11/16/18-related external genital lesions and genital warts in males aged 16 to 26 years. In the 4,065-participant, 18-country trial, efficacy against vaccine-type external genital lesions was 90.4% (95% CI 69.2 to 98.1) in the per-protocol population uninfected with the relevant types, but 65.5% (95% CI 45.8 to 78.6) in the intention-to-treat population that included prior infection. Per-protocol efficacy against genital warts was 89.4%. These are actual lesion endpoints, but protection is vaccine-type-specific, the strongest estimates are per-protocol, and pivotal evidence is concentrated in one manufacturer-funded trial, supporting B rather than A.
ads claimClaims that vaccination prevents every HPV type and every genital lesion expand four-type prevention into protection against non-vaccine types or treatment of existing infection. This is a prophylactic vaccine and works best before exposure to the relevant types.
Useful facts when choosing a product
- The quadrivalent HPV vaccine is a prescription prophylactic vaccine containing recombinant L1 virus-like particles from HPV types 6, 11, 16, and 18 and is marketed as Gardasil.
- It prevents new infections and their resulting lesions but does not treat an established HPV infection or existing genital warts.
- Injection-site pain, redness, swelling, fever, and headache can occur, and adolescents or young adults should be observed for syncope after vaccination.
- Clinical trials and long-term follow-up support a generally favorable safety profile, while national immunization guidance and the product label determine schedules, contraindications, and reasons to defer a dose.
What the research actually shows
Giuliano and colleagues enrolled 4,065 healthy males aged 16 to 26 years at 71 sites in 18 countries and assigned them to quadrivalent HPV vaccine or an aluminum-adjuvant control. In the intention-to-treat population, all external genital lesions numbered 36 versus 89, for observed efficacy of 60.2%; efficacy against HPV 6/11/16/18-related lesions was 65.5% by intention to treat and 90.4% per protocol. Genital warts made up most lesions, with per-protocol efficacy of 89.4%. An open-label extension supports protection for up to ten years, but because randomized placebo control did not continue throughout, the base trial carries the main grading weight.
Why this is classified as B (76)
A 4,065-participant multinational randomized double-blind trial substantially reduced actual HPV 6/11/16/18-related external genital lesions and genital warts. Intention-to-treat efficacy against vaccine-type lesions was 65.5%, compared with per-protocol lesion and wart efficacy of 90.4% and 89.4%. Restriction to four types, reliance on the uninfected per-protocol population for the strongest estimates, a mostly less-severe lesion endpoint, and one pivotal Merck-funded trial yield B with 76 points. Injection reactions and syncope remain separate safety issues.
Counterpoint. This does not mean that every recipient needs testing for all prior HPV infections before vaccination. It does mean that the vaccine is not therapy for an already established type or an existing wart, and prevention is strongest before exposure.
Rejudgment record. New verdict — Accepted direct lesion evidence in the 4,065-participant multinational trial, including 90.4% per-protocol efficacy against HPV 6/11/16/18-related external genital lesions and 89.4% efficacy against warts, while accounting for vaccine-type and uninfected per-protocol restriction, 65.5% intention-to-treat efficacy, one pivotal manufacturer-funded trial, and endpoint severity
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of HPV 6/11/16/18-related external genital lesions in males aged 16 to 26 years | B | Actual lesions were reduced with 90.4% per-protocol and 65.5% intention-to-treat efficacy, but effect varied by vaccine type and prior exposure. |
| Prevention of vaccine-type genital warts in males aged 16 to 26 years | B | Per-protocol efficacy against genital warts was 89.4%, and warts made up most lesion endpoints. |
| Treatment of an existing relevant HPV-type infection or genital wart | D | The prophylactic vaccine trial did not establish treatment of existing infection or lesions, and efficacy was lower when prior exposure was included. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multinational randomized double-blind placebo-controlled trial | 4,065 | Merck and other support | External genital lesions and genital warts related to HPV 6/11/16/18 | Vaccine-type lesion efficacy was 90.4% per protocol and 65.5% by intention to treat; per-protocol wart efficacy was 89.4%. | Pivotal randomized trial with direct lesion endpoints |
| Study 2 | Open-label long-term extension of a randomized trial | 10 | Merck Sharp & Dohme | Long-term incidence of vaccine-type external genital warts and external genital lesions | Low incidence of vaccine-type warts and external genital lesions persisted during long-term follow-up of the early-vaccination group. | Supportive durability evidence from a nonrandomized extension |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-22).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-22 · Corrections: none
Cite this verdict
[Chamgap] Quadrivalent HPV vaccine x prevention of external genital lesions and genital warts in males aged 16 to 26 years — Evidence Grade B·76. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/quadrivalent-hpv-vaccine-male-external-genital-lesions/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.